No Data
No Data
IDEAYA Biosciences Is Maintained at Buy by Citigroup
IDEAYA Biosciences Is Maintained at Buy by Citigroup
Express News | Citigroup Maintains Buy on IDEAYA Biosciences, Raises Price Target to $60
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), IDEAYA Biosciences (IDYA) and Vor Biopharma (VOR)
Strong Buy Rating for IDEAYA Biosciences Based on Strategic Partnership and Promising Oncology Pipeline
Express News | Ideaya Biosciences Has Entered Into A Clinical Trial Collaboration And Supply Agreement With Merck To Evaluate Its IDEE161 In Combination With Keytruda (Pembrolizumab) For Endometrial Cancer, In A Phase 1 Trial
Big Pharma Patent Cliffs Seen Fueling Oncology M&A This Year
No Data